These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3274858)

  • 1. Desensitization--which renal allograft recipients are suitable?
    Thick M
    Transplant Proc; 1987 Feb; 19(1 Pt 1):738-9. PubMed ID: 3274858
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of cytotoxicity against donor HLA markers by posttransplant sera from renal allograft recipients.
    Gülay Z; Bora S; Kavukçu S; Mehr MA; Elverdi B; Gülay H
    Transplant Proc; 1995 Oct; 27(5):2683-4. PubMed ID: 7482874
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of repeated HLA mismatches on the outcome of renal allograft retransplantation.
    Povlsen JV; Madsen M; Birkeland SA; Løkkegaard H; Pedersen EB; Svejgaard A; Olgaard K; Fjeldborg O
    Transplant Proc; 1992 Feb; 24(1):307-8. PubMed ID: 1539288
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of reexposure to mismatched major histocompatibility complex antigens on renal retransplant allograft survival.
    Farney AC; Noreen HJ; Sutherland DE; Reinsmoen N; Segall M; Gillingham K; Schmidt WJ; Matas AJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):213-4. PubMed ID: 8438275
    [No Abstract]   [Full Text] [Related]  

  • 5. Bw4/Bw6 matching and renal allograft survival in homozygous recipients.
    Spreng WM; Nathan P; First MR
    Proc Clin Dial Transplant Forum; 1979; 9():93-4. PubMed ID: 399520
    [No Abstract]   [Full Text] [Related]  

  • 6. Importance of HLA matching in highly sensitised renal transplant recipients with high transplant survival rates. The Manchester Kidney Transplant Team.
    Martin S; Connolly J; Jos V
    Transplant Proc; 1993 Feb; 25(1 Pt 1):265-6. PubMed ID: 8438295
    [No Abstract]   [Full Text] [Related]  

  • 7. HLA antigens in kidney allograft rejection.
    Sujirachato K; Chiewsilp P; Jirasiritham S; Mongkolsuk T; Sumethkul V
    Transplant Proc; 1996 Jun; 28(3):1272. PubMed ID: 8658656
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of anti-HLA antibodies on the long-term survival of heart and kidney allografts.
    Barr ML; Cohen DJ; Benvenisty AI; Hardy M; Reemtsma K; Rose EA; Marboe CC; D'Agati V; Suciu-Foca N; Reed E
    Transplant Proc; 1993 Feb; 25(1 Pt 1):262-4. PubMed ID: 8438294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-DR matching is effective in reducing posttransplant costs in renal allograft recipients on triple therapy.
    Taylor CJ; Bayne AM; Welsh KI; Morris PJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):210-1. PubMed ID: 8438273
    [No Abstract]   [Full Text] [Related]  

  • 10. A probable mechanism for allograft rejection in HLA-identical combinations.
    Brasile L; Clarke J; Cerilli J
    Transplant Proc; 1987 Feb; 19(1 Pt 1):894-5. PubMed ID: 3274884
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive antiglobulin cytotoxicity crossmatch in renal allograft recipients treated with cyclosporine.
    Gifford RR; Doran MM; Ruth JA; Coppage ML; Winsett OE; Fish JC
    Transplantation; 1986 Oct; 42(4):439-41. PubMed ID: 3532456
    [No Abstract]   [Full Text] [Related]  

  • 13. Longitudinal testing of seventy-six renal allograft patients for HLA antibodies: Maastricht experience.
    van den Berg-Loonen EM; Terasaki P; Kohanof S; Christiaans MH
    Clin Transpl; 2006; ():305-22. PubMed ID: 18365386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cadaveric kidney exchange on the basis of HLA-matching is already cost-effective in the first year after grafting.
    Christiaans MH; van den Berg-Loonen PM; Nieman FH; Cohen B; Kootstra G; van Hooff JP
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1685-6. PubMed ID: 8442236
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of the effects of cyclosporine and HLA-typed source leukocyte transfusions (apheresis by-products) on the immune systems of highly sensitized prospective renal allograft recipients.
    Weir MR; Shen SY; Dagher FJ; Bentley FR; Lesko L; Sadler JH
    Transplant Proc; 1987 Feb; 19(1 Pt 1):735-7. PubMed ID: 3547838
    [No Abstract]   [Full Text] [Related]  

  • 16. Reduction of the center effect by HLA matching.
    Gjertson DW; Terasaki PI; Cecka JM; Takemoto S
    Transplant Proc; 1993 Feb; 25(1 Pt 1):215-6. PubMed ID: 8438276
    [No Abstract]   [Full Text] [Related]  

  • 17. [The role of immunogenetics in renal transplantation: HLA-matches and mismatches].
    Müller CA; Müller GA
    Dtsch Med Wochenschr; 2009 Aug; 134(34-35):1692-6. PubMed ID: 19707968
    [No Abstract]   [Full Text] [Related]  

  • 18. HLA amino acid residue matching in 2575 kidney transplants.
    Tan J; Qiu J; Tang X
    Transplant Proc; 2007 Jun; 39(5):1429-31. PubMed ID: 17580154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation.
    Bingaman AW; Murphey CL; Palma-Vargas J; Wright F
    Transplantation; 2008 Dec; 86(12):1864-8. PubMed ID: 19104435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does re-exposure to mismatched HLA antigens decrease renal re-transplant allograft survival?
    Farney AC; Matas AJ; Noreen HJ; Reinsmoen N; Segall M; Schmidt WJ; Gillingham K; Najarian JS; Sutherland DE
    Clin Transplant; 1996 Apr; 10(2):147-56. PubMed ID: 8664509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.